Laurus & Sai Life management.
Here are the key takeaways from the discussion on the CDMO (contract development and manufacturing organisation) space.
Revenue and lumpy growth
-
CDMO revenue mix: There are two streams – commercial stage molecules and clinical phase molecules; clinical revenues are highly cyclical and volatile.
-
Quarterly vs annual view: Even for commercial molecules, numbers should be judged on yearly performance, not quarter-on-quarter, because of inherent lumpiness.
-
Company-specific impact: Some firms are doing well while others are weak; the current correction in CDMO stocks (40–70% from 52‑week highs) is not an industry-wide structural issue but more company-specific.
Drivers of guidance cuts and growth
-
Growth visibility: Guidance cuts by some companies are linked to molecule uptake and vendor diversification (how many suppliers a pharma innovator uses and how volumes are shared).
-
Partner de-risking: Innovators are adding additional vendors to de-risk supply chains, which influences revenue distribution and growth for any single CDMO.
-
Inventory destocking: Inventory stocking/destocking happens across the industry depending on launch quantities, achieved market share, and sell-out; it is part of the normal cycle, not necessarily a structural problem.
Tactical vs strategic supplier shift
-
From tactical to strategic: Indian CDMOs are transitioning from being “tactical” suppliers (one or two big molecules with outsized impact) to “strategic” partners with a broad molecule and technology base.
-
Diversified portfolio: Once a CDMO becomes a strategic supplier with a wider portfolio, quarterly swings remain but become less extreme; the key is breadth across commercial and development pipelines.
-
Product concentration risk: Current volatility is more a product-concentration issue than an inventory issue; firms with too much dependence on a few molecules see sharper swings.
Long-term outlook and cycle
-
Multi-year growth cycle: Industry veterans see Indian CDMOs in the early phase of a multi-year (5–10 year) growth cycle, not yet in the “reaping” phase.
-
Investment phase: To become true strategic partners, CDMOs must invest in a broad range of technologies and capacities; markets may be misjudging this investment phase as a period of underperformance.
-
Time horizon: This is described as a 10–15 year relationship-building journey; short 1–2 year snapshots or one-off events like specific US acts should not drive the full thesis.
Geopolitics, China, and the Biosecure Act
-
Biosecure Act: The US Biosecure Act is now seen as “immaterial” or largely noise; the bigger themes are global diversification and geopolitics.
-
China risk: Customers cannot keep 80% of their supply chain in China, which is a strategic competitor; geographic diversification of suppliers is “here to stay,” structurally benefiting India.
RFPs vs real business
-
RFPs overplayed: RFP (request for proposal) numbers are being overemphasised by the market; many RFPs are exploratory and not serious business leads.
-
Relationship-led conversion: Serious RFPs and sustainable business come from deep customer relationships and strategic partnerships, not one-off bid processes.
-
Metrics to track: Investors should focus on strategic pipeline quality, customer base, and breadth of technologies rather than headline RFP values as “predictive metrics.”